Searchable abstracts of presentations at key conferences in endocrinology

ea0011p499 | Endocrine tumours and neoplasia | ECE2006

Long-term somatostatin analog octreotide treatment in insulinoma patients

Vezzosi D , Bennet A , Courbon F , Caron P

The usefulness of long-term medical treatment with somatostatin analogs has not been evaluated in insulinomas. 22 patients with hypoglycaemia related to endogenous hyperinsulinism (62±21 years, M±S.D., 27–88 years) were not treated by surgery: aged patients (n=10), patients with malignant unresectable insulinomas (n=6; locally invasive, n=1; multimetastatic, n=5), multiple insulinomas (n=2), diffuse beta cell pat...

ea0029p1432 | Pituitary Clinical | ICEECE2012

Decreased IGF1 levels and GH-resistant hepatic state to estrogens during the first trimester of pregnancy in non-acromegalic women

Persechini M. , Gennero I. , Grunenwald S. , Vezzosi D. , Bennet A. , Caron P.

Introduction: In women with GH-secreting pituitary adenoma, a decrease of IGF1 levels has been reported during the first trimester of pregnancy, before placental GH (pGH) secretion inducing a progressive increase in IGF1 levels throughout gestation. This decrease has been related to hepatic GH-resistant state, via JAK2/STAT pathway, due to increased estrogen (E2) levels.Objectives: Evaluate IGF1 change in non-acromegalic women during the first...

ea0026p55 | Endocrine tumours and neoplasia | ECE2011

Diagnosis of post-surgical recurrence in patients with malignant insulinoma

Buffet A , Vezzosi D , Maiza J-C , Grunenwald S , Bennet A , Otal Ph , Carrere N , Caron Ph

Context: The post-surgical follow-up of malignant insulinomas is often marked by recurrence after initial remission. However, the criteria for the diagnosis of recurrence of these malignant endocrine tumors are not well defined in the literature, unlike diagnostic of criteria for hyperinsulinemic hypoglycaemia (Cryer 2009). We retrospectively reviewed the criteria that allowed the diagnosis of recurrence in four patients with malignant insulinoma after initial post-operative r...

ea0029oc7.1 | Adrenal Clinical | ICEECE2012

Progression-free survival without treatment of malignant pheochromocytoma and paraganglioma at one year

Hescot S. , Leboulleux S. , Amar L. , Borget I. , Vezzosi D. , Libe R. , Niccoli P. , Borson-Chazot F. , Do Cao C. , Tabarin A. , de la Fouchardiere C. , Raingeard I. , Chougnet C. , Gimenez-Roqueplo A. , Young J. , Bertherat J. , Wemeau J. , Bertagna X. , Schlumberger M. , Plouin P. , Baudin E.

Pheochromocytoma and paraganglioma are defined as malignant by the occurence of metastasis in extra paraganglionic sites. The natural evolution of these tumors remains unknown.The aim of our retrospective study was to define the progression-free survival (PFS) of untreated Malignant Pheochromocytoma and Paraganglioma (MPP) at 12 months (12 m-PFS) and to look for prognostic markers of 12 m-PFS. We analyzed clinical parameters of patients followed within 8...